# Mantle Cell Lymphoma with Persistent Massive Pleural Effusions Requiring Invasive Mechanical Ventilation and Bilateral Continuous Thoracic Drainage

**Authors:** Taichiro Tokura, Youhei Imai, Satoshi Sakai, Reina Saga, Hiroko Hidai, Sayuri Motomura

PMC · DOI: 10.3390/reports9010038 · Reports - Clinical Practice and Surgical Cases · 2026-01-27

## TL;DR

A rare case of mantle cell lymphoma caused severe lung fluid buildup requiring ventilation and chest drainage, but treatment led to full recovery.

## Contribution

Reports a rare clinical case of MCL with massive pleural effusions requiring mechanical ventilation and bilateral drainage.

## Key findings

- Pleural effusions subsided after immunochemotherapy, allowing extubation and removal of chest tubes.
- Complete remission was achieved with resolution of lymphadenopathy and bone marrow infiltration.
- Prompt diagnosis and treatment were critical for managing this rare MCL complication.

## Abstract

Background and Clinical Significance: Mantle cell lymphoma (MCL) frequently involves bone marrow, gastrointestinal tract, and hepatosplenomegaly, whereas pleural effusions are uncommon. Cases requiring invasive mechanical ventilation and thoracic drainage are rare. We report a case of MCL with persistent massive pleural effusions requiring invasive mechanical ventilation and bilateral continuous thoracic drainage. Case Presentation: A 71-year-old woman presented with dyspnea and was found to have bilateral pleural effusions and generalized lymphadenopathy. Shortly after admission, she developed acute respiratory failure due to pleural effusions and required invasive mechanical ventilation. Right-sided continuous thoracic drainage was initiated. Thereafter, more than 1 L of pleural fluid was drained each day. Flow cytometry of the pleural fluid showed CD5-positive B cells with kappa light-chain restriction. Bone marrow examination revealed abnormal lymphocyte infiltration. Cervical lymph node biopsy demonstrated diffuse proliferation of medium-sized, abnormal B lymphocytes with an immunophenotype of CD5+, CD19+, CD20+, cyclin D1+, SOX11+, and κ+, with a Ki-67 index of 20%, confirming MCL, stage IV. Immunochemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) was commenced under mechanical ventilation. Shortly thereafter, left-sided continuous thoracic drainage was also initiated. However, in response to immunochemotherapy, the bilateral pleural effusions gradually subsided, enabling extubation, and there was no reaccumulation after removal of both chest tubes. Furthermore, generalized lymphadenopathy regressed, and bone marrow examination revealed resolution of lymphoma infiltration, resulting in complete remission. Conclusions: De novo MCL complicated by persistent massive pleural effusions requiring invasive mechanical ventilation and bilateral continuous thoracic drainage is rare. A thorough diagnostic workup followed by prompt initiation of immunochemotherapy can arrest pleural output, enable extubation, and be lifesaving. Clinicians should recognize that MCL rarely presents with persistent massive pleural effusions.

## Linked entities

- **Proteins:** CD5 (CD5 molecule), CD19 (CD19 molecule), MS4A1 (membrane spanning 4-domains A1), ccnd1.S (cyclin D1 S homeolog), SOX11 (SRY-box transcription factor 11), k (kidney)
- **Chemicals:** cyclophosphamide (PubChem CID 2907), doxorubicin (PubChem CID 31703), vincristine (PubChem CID 5978), prednisone (PubChem CID 5865)
- **Diseases:** mantle cell lymphoma (MONDO:0018876), acute respiratory failure (MONDO:0001208)

## Full-text entities

- **Genes:** CD19 (CD19 molecule) [NCBI Gene 930] {aka B4, CVID3}, FCER2 (Fc epsilon receptor II) [NCBI Gene 2208] {aka BLAST-2, CD23, CD23A, CLEC4J, FCE2, FCErII}, BTK (Bruton tyrosine kinase) [NCBI Gene 695] {aka AGMX1, AT, ATK, BPK, IGHD3, IMD1}, CD5 (CD5 molecule) [NCBI Gene 921] {aka LEU1, T1}, CCND1 (cyclin D1) [NCBI Gene 595] {aka BCL1, D11S287E, PRAD1, U21B31}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, SOX11 (SRY-box transcription factor 11) [NCBI Gene 6664] {aka CSS9, IDDMOH, MRD27}, MME (membrane metalloendopeptidase) [NCBI Gene 4311] {aka CALLA, CD10, CMT2T, NEP, SCA43, SFE}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, BCL6 (BCL6 transcription repressor) [NCBI Gene 604] {aka BCL5, BCL6A, LAZ3, ZBTB27, ZNF51}, KRT20 (keratin 20) [NCBI Gene 54474] {aka CD20, CK-20, CK20, K20, KRT21}, BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596] {aka Bcl-2, PPP1R50}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, IL2RB (interleukin 2 receptor subunit beta) [NCBI Gene 3560] {aka CD122, IL15RB, IMD63, P70-75}, IGH (immunoglobulin heavy locus) [NCBI Gene 3492] {aka IGD1, IGH.1@, IGH@, IGHD@, IGHDY1, IGHJ}
- **Diseases:** lymphadenopathy (MESH:D008206), acute respiratory failure (MESH:D012131), lymphoma (MESH:D008223), Pleural Effusions (MESH:D010996), B-cell lymphoma (MESH:D016393), splenomegaly (MESH:D013163), NHL (MESH:D008228), tuberculosis (MESH:D014376), Lymphoma, Mantle-Cell (MESH:D020522), hydrothorax (MESH:D006876), CR (MESH:D012075), DLBCL (MESH:D016403), TB (MESH:D014390), stage III (MESH:D062706), lymphocytosis (MESH:D008218), malignant effusion (MESH:D016066), cervical lymphadenopathy (MESH:D002575), infectious (MESH:D003141), injury to (MESH:D014947), chylothorax (MESH:D002916), Death (MESH:D003643), hemothorax (MESH:D006491), effusion (MESH:D000080324), serous effusions (MESH:D018297), pleural (MESH:D010995), hepatosplenomegaly (MESH:C535727), dyspnea (MESH:D004417), tumor (MESH:D009369), toxicity (MESH:D064420), lower extremity edema (MESH:D004487)
- **Chemicals:** ibrutinib (MESH:C551803), acalabrutinib (MESH:C000604908), prednisone (MESH:D011241), eosin (MESH:D004801), glucose (MESH:D005947), glofitamab (MESH:C000720108), cyclophosphamide (MESH:D003520), BR (-), doxorubicin (MESH:D004317), oxygen (MESH:D010100), Hematoxylin (MESH:D006416), vincristine (MESH:D014750), rituximab (MESH:D000069283), bendamustine (MESH:D000069461)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** ZUMA-2 — Homo sapiens (Human), Colon carcinoma, Cancer cell line (CVCL_A628)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12921971/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12921971/full.md

## References

32 references — full list in the complete paper: https://tomesphere.com/paper/PMC12921971/full.md

---
Source: https://tomesphere.com/paper/PMC12921971